Work

A Novel SET Antagonist (OP449) Is Cytotoxic to CML Cells, Including the Highly-Resistant BCR-ABLT315I Mutant, and Demonstrates Enhanced Efficacy in Combination with ABL Tyrosine Kinase Inhibitors,

Year: 2011

Type: article

Source: Blood

DOI: 10.1182/blood.v118.21.3757.3757

Authors: Anupriya Agarwal, Ryan MacKenzie, Jessica Oddo, Michael P Vitek, Dale J. Christensen, Brian J. Druker

Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Oncotide Pharmaceuticals (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2980077127

FWCI: 1.514

Cites:

Cited by: 14

Related to: 10